Fibroses, Pulmonary
Conditions
Brief summary
A study is being conducted to evaluate the efficacy and safety of Longidaze for the prevention and treatment of post-inflammatory pulmonary fibrosis and interstitial lung disease following COVID-19.
Detailed description
The aim of the study is to compare the outcomes associated with postinflammatory pulmonary fibrosis and interstitial lung disease among a cohort of adult patients after complicated pulmonary manifestations of COVID-19 in two groups: in a group of patients who were prescribed Longidaze® for treatment or prevention as part of routine clinical practice, and in the group of patients who underwent dynamic observation.
Interventions
DRUGbovhyaluronidase azoxymer
3000 IU intramuscularly once every 5 days with a course of 15 injections
Sponsors
NPO Petrovax
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with residual lung changes after complicated COVID-19 2. Residual changes were detected no later than 2 months after the discharge after disease 3. Treatment of COVID-19 was in accordance with the standard of the then current temporary guidelines for the treatment of COVID-19 4. Age of patients over 18 years old 5. Negative polymerase chain reaction (PCR) test COVID-19 at least 2 times in respiratory samples or based on serology results in blood samples 6. Patients in the framework of routine clinical practice, in accordance with the instructions for use before inclusion in the study, were prescribed intramuscular treatment with Longidaze® at a dose of 3000 IU, 1 injection every 5 days for a total course of 15 injections or dynamic observation without the use of active therapy 7. The patient did not participate in other drug clinical trials within 1 month prior to Visit 1. 8. The patient or patient's caregiver agrees to participate in the trial and sign an informed consent form 9. Patient understands and agrees to follow the planned procedures. 10. Women with fertile potential must agree to use at least one method of contraception before completing participation in the study.
Exclusion criteria
1. Women during pregnancy and lactation and women planning to become pregnant during the study period 2. Severe background diseases, such as severe heart failure (class IV heart function), severe liver and kidney disease, severe bronchial asthma, severe chronic obstructive pulmonary disease, bronchiectasis, bullous emphysema and previously identified interstitial lung diseases, neurological diseases, tumors. 3. Long-term bed rest, regardless of its cause 4. Increased individual sensitivity to the components of the studied drug 5. Pathological conditions that determine the impossibility of patient participation in the study (by the decision of the investigator) 6. Medical history that, according to the investigator, does not allow the patient to be included in the study 7. A burdened allergic anamnesis, which, according to the investigator, does not allow the patient to be included in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The severity of lung tissue lesions with fibrosis and interstitial changes on day 75 | Day 0, Day 75 | The severity of pulmonary tissue lesions with fibrosis and interstitial changes (%) according to high resolution computed tomography examination relative to the baseline value after 2.5 months in patients of the Longidaze® group compared with the dynamic observation group according to the results of a blinded central laboratory |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The severity of lung tissue damage by fibrosis and interstitial changes (%) on day 180 | Day 0, Day 180 | The severity of lung tissue damage by fibrosis and interstitial changes (%) according to high resolution computed tomography examination relative to the baseline value after 6 months in relation to the baseline values of the indicator in patients of the Longidaze® group in comparison with the the dynamic observation group (according to the results of a blinded central laboratory) |
| The severity of lung tissue lesions with fibrosis and interstitial changes (%) on day 75 and day 180 | Day 0, Day 75, Day 180 | The severity of lung tissue lesions with fibrosis and interstitial changes (%) according to high resolution computed tomography examination relative to the baseline value after 2.5 months and 6 months in patients of the Longidaze® group compared with the the dynamic observation group (according to the results of the local laboratory) |
| The severity of lesions of the lung tissue with fibrosis and interstitial changes and indicators: frosted glass, hydrothorax, consolidation (%) images analyzed by the Botkin.AI program (artificial intelligence) | Day 75, Day 180 | The severity of lesions of the lung tissue with fibrosis and interstitial changes and indicators: frosted glass, hydrothorax, consolidation (%) based on the high-resolution computed tomography images analyzed by the Botkin.AI program (artificial intelligence) and then verified by a specialist after 2.5 months and 6 months from the beginning of observation in relation to the baseline values of indicators in patients of the Longidaze® group in comparison with the dynamic observation group |
| Change in forced vital capacity (FVC) | Day 0, Day 75, Day 180 | Change in forced vital capacity FVC (%) relative to the baseline value after 2.5 months and 6 months in patients of the Longidaze® group compared with the the dynamic observation group |
| Change in the diffusion capacity of the lungs | Day 0, Day 75, Day 180 | Change in the diffusion capacity of the lungs (%) relative to the baseline value after 2.5 months and 6 months in patients of the Longidaze® group compared with the the dynamic observation group |
| Change in the degree of dyspnea on the MMRC scale | Day 0, Day 75, Day 180 | Change in the degree of dyspnea on the MMRC scale from baseline after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group. MMRC scale (Modified Medical Research Council scale) 0 - no - Dyspnea does not bother, except for very intense exercise 1. \- mild - Shortness of breath bothers with brisk walking or climbing a small elevation 2. \- moderate to severe - Shortness of breath results in slower walking compared to other people of the same age, or need to stop while walking at normal pace on a level surface 3. \- Severe - Shortness of breath makes you stop when walking about 100 m or after a few minutes of walking on a flat surface 4. \- very severe - Shortness of breath makes it impossible to leave the house or appears when dressing and undressing |
| Changes in capillary blood oxygen saturation (SpO2) | Day 0, Day 75, Day 180 | Changes in SpO2 of capillary blood relative to the initial value after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group. |
| Changes in the covered footage in the 6-minute walk test | Day 0, Day 75, Day 180 | Changes in the covered footage in the 6-minute walk test after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group. |
| Changes in capillary blood saturation (SpO2) after a 6-minute walk test | Day 0, Day 75, Day 180 | Changes in capillary blood saturation (SpO2) after a 6-minute walk test after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group. |
| Change in the residual volume of the lungs | Day 0, Day 75 | Change in the residual volume of the lungs after 2.5 months in patients of the Longidaze® group compared with the dynamic observation group. |
| Change in the total lung capacity | Day 0, Day 75 | Change in the total lung capacity after 2.5 months in patients of the Longidaze® group compared with the dynamic observation group. |
| Change in inspiratory capacity | Day 75 | Change in inspiratory capacity after 2.5 months in patients of the Longidaze® group compared with dynamic observation group |
Countries
Russia
Outcome results
None listed